Clearance of increased serum advanced glycosylation end products in patients with end stage renal disease by hemodialysis

AIM: To study the effect of removal of hemodialysis using acetate membrane on serum advanced glycosylation end products (AGEP) in 36 patients (59.1 +/ - 1.6) with end stage, renal disease (ESRD). METHODS: Serum AGEP levels wer e determined with quantitative fluorescence spectrometry, how injection ana lysis (FIA), and competitive enzyme-linked immunosorbent assay (ELISA) usin g a polyclonal antibody directed against AGEP. RESULTS: The serum AGEP leve ls in patients with ESRD quantified by fluorescence spectrometry, FIA, and ELISA were higher than those in controls [(25 +/- 5) vs (7.5 +/- 1.5), (6.1 +/- 1.8) vs (1.4 +/- 0.5), and (37 +/- 20) vs (9 +/- 10) kU/L, respectivel y] and markedly reduced to [(22 +/- 6), (4.2 +/- 1.4), and (19 +/- 14) kU/L , respectively] after hemodialysis. CONCLUSION: Increased serum AGEP levels in the circulation of patients with ESRD were reduced effectively by hemod ialysis.